Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Free Cash Flow: 2019-2024

Historic Free Cash Flow for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$356.2 million.

  • Beam Therapeutics' Free Cash Flow rose 3.58% to -$86.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$352.4 million, marking a year-over-year decrease of 142.38%. This contributed to the annual value of -$356.2 million for FY2024, which is 94.72% down from last year.
  • Beam Therapeutics' Free Cash Flow amounted to -$356.2 million in FY2024, which was down 94.72% from -$182.9 million recorded in FY2023.
  • Beam Therapeutics' 5-year Free Cash Flow high stood at -$26.4 million for FY2022, and its period low was -$356.2 million during FY2024.
  • In the last 3 years, Beam Therapeutics' Free Cash Flow had a median value of -$182.9 million in 2023 and averaged -$188.5 million.
  • As far as peak fluctuations go, Beam Therapeutics' Free Cash Flow soared by 76.63% in 2022, and later slumped by 592.28% in 2023.
  • Beam Therapeutics' Free Cash Flow (Yearly) stood at -$112.1 million in 2020, then declined by 0.88% to -$113.1 million in 2021, then skyrocketed by 76.63% to -$26.4 million in 2022, then tumbled by 592.28% to -$182.9 million in 2023, then plummeted by 94.72% to -$356.2 million in 2024.